Insightec

Executive Summary

Insightec is a commercial-stage medical technology company pioneering incisionless, image-guided focused ultrasound therapy. Its flagship Exablate Neuro platform, utilizing magnetic resonance-guided focused ultrasound (MRgFUS), is FDA-approved for medication-refractory essential tremor and tremor-dominant Parkinson's disease. The procedure offers a non-invasive, same-day outpatient alternative to deep brain stimulation or radiosurgery, with growing adoption across leading neurosurgical centers. Despite a proven technology and favorable safety profile, Insightec faces challenges in expanding its addressable market beyond current indications, competition from established surgical modalities, and the need for broader reimbursement coverage. The company is actively pursuing clinical development in new therapeutic areas such as neuropathic pain, obsessive-compulsive disorder, and potentially Alzheimer's disease, leveraging its platform's ability to precisely ablate or modulate brain tissue without incisions. With a strong intellectual property portfolio and strategic partnerships, Insightec is well-positioned to capture share in the functional neurosurgery market, though near-term growth remains tethered to procedural volumes and regulatory expansion. The company's private status limits visibility into financials, but its commercialization trajectory and pipeline progress suggest moderate upside potential.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for treatment of neuropathic pain50% success
• Q2 2027Publication of pivotal trial results for obsessive-compulsive disorder40% success
• Q3 2026Strategic partnership for distribution in Asia-Pacific region60% success